Hims & Hers Partners with Novo Nordisk to Expand Access to Obesity Care

Hims & Hers Health, Inc. (NYSE: HIMS) announced today a new long-term collaboration with Novo Nordisk aimed at improving access to obesity care treatments. As the first phase of the partnership, the companies launched a bundled offering that makes Novo Nordisk's FDA-approved obesity medication Wegovy(R) available directly through the Hims & Hers platform.

The bundled package, now live on the platform, includes all available doses of Wegovy(R), paired with a Hims & Hers membership that provides 24/7 clinical support, nutrition guidance, and ongoing care -- all priced from $599 per month. This streamlined offering brings together prescription access and continuous health support at a single, unified price point.

Hims & Hers CEO Andrew Dudum stated that the collaboration reflects a shared vision of a consumer-first approach to healthcare and is just the beginning of broader initiatives the companies plan to roll out. Similarly, Dave Moore, Executive Vice President at Novo Nordisk, emphasized that combining Novo Nordisk's medications with Hims & Hers' scalable platform could lead to improved long-term outcomes for people living with chronic conditions like obesity.

Beyond this initial bundled offering, the companies are working on a broader roadmap to integrate innovative treatments with a more accessible and affordable care delivery model.

Hims & Hers' announcement was not the only weight loss and GLP-1 focused news today as multiple emergers such as WeightWatchers (WW) and LifeMD (LFMD) experienced share price appreciation after announcing partnerships and platform expansions.

The post Hims & Hers Partners with Novo Nordisk to Expand Access to Obesity Care appeared first on PRISM MarketView.

COMTEX_465045147/2927/2025-04-29T14:31:01